Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
If you want the direct side-by-side version, see our BPC-157 vs TB-500 comparison
BPC157 (Body Protection Compound157) is a synthetic peptide fragment derived from a protective gastric protein
If the agency ultimately issues a final determination against listing, compounders would lose any viable legal pathway though substances can be re-nominated in future PCAC cycles or challenged in federal court
C.TakeuchiO.HuangZ.FisherJ
Both remain in phase 3 clinical development programs [16]: Cagrilintide Status: Phase 3 trials ongoing for CagriSema (cagrilintide + semaglutide combination) Expected approval timeline: 2027-2028 for the combination product Monotherapy development pathway unclear Retatrutide Status: Phase 3 trials initiated in 2024-2025 Monotherapy development for obesity and metabolic dysfunction Expected approval timeline: 2028-2029 if trials succeed This regulatory status means any use of these compounds, whether individually or in cagrilintide dosage with retatrutide combinations, occurs in research contexts or through off-label prescribing once (if) individual approvals are obtained
US$ 23.94
US$ 25.86
US$ 28.35
US$ 28.65
